

# Jian-Ying Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10561496/publications.pdf>

Version: 2024-02-01

78  
papers

3,418  
citations

159585

30  
h-index

149698

56  
g-index

81  
all docs

81  
docs citations

81  
times ranked

3820  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoantibody to GNAS in Early Detection of Hepatocellular Carcinoma: A Large-Scale Sample Study Combined with Verification in Serial Sera from HCC Patients. <i>Biomedicines</i> , 2022, 10, 97.	3.2	3
2	Immunoseroproteomic profiling in autoantibody to ENO1 as potential biomarker in immunodiagnosis of osteosarcoma by serological proteome analysis (SERPA) approach. <i>OncolImmunology</i> , 2021, 10, .	4.6	2
3	Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma. <i>Molecular Medicine</i> , 2021, 27, 15.	4.4	10
4	Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness. <i>EMBO Reports</i> , 2021, 22, e50922.	4.5	20
5	Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6139.	4.1	18
6	Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility. <i>World Journal of Gastroenterology</i> , 2021, 27, 4653-4666.	3.3	12
7	Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 691769.	3.5	5
8	Overexpression of p62/IMP2 can Promote Cell Migration in Hepatocellular Carcinoma via Activation of the Wnt/ $\beta$ -Catenin Pathway. <i>Cancers</i> , 2020, 12, 7.	3.7	29
9	Regulation of MicroRNA-497-Targeting AKT2 Influences Tumor Growth and Chemoresistance to Cisplatin in Lung Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 840.	3.7	9
10	MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway. <i>EBioMedicine</i> , 2019, 46, 66-78.	6.1	21
11	Glycine, serine and threonine metabolism confounds efficacy of complement-mediated killing. <i>Nature Communications</i> , 2019, 10, 3325.	12.8	118
12	Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 835-841.	4.2	22
13	Long Noncoding RNA HOST2 Promotes Epithelial-Mesenchymal Transition, Proliferation, Invasion and Migration of Hepatocellular Carcinoma Cells by Activating the JAK2-STAT3 Signaling Pathway. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 301-314.	1.6	32
14	Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769913.	1.8	16
15	Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer. <i>OncolImmunology</i> , 2017, 6, e1310359.	4.6	43
16	Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer. <i>Tumor Biology</i> , 2017, 39, 101042831771166.	1.8	27
17	Proteomic-based identification of HSP70 as a tumor-associated antigen in ovarian cancer. <i>Oncology Reports</i> , 2017, 37, 2771-2778.	2.6	9
18	Identification of 14â€“3-31¶ as a potential biomarker in gastric cancer by proteomics-based analysis. <i>Molecular Medicine Reports</i> , 2017, 16, 7759-7765.	2.4	8

#	ARTICLE	IF	CITATIONS
19	Serum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer. <i>Oncolmmunology</i> , 2016, 5, e1138200.	4.6	28
20	Autoantibodies against tumor-associated antigens in the early detection of lung cancer. <i>Lung Cancer</i> , 2016, 99, 172-179.	2.0	62
21	A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1233-1242.	4.2	24
22	Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer. <i>Prostate</i> , 2016, 76, 1375-1386.	2.3	25
23	The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. <i>Biomedicine and Pharmacotherapy</i> , 2016, 82, 595-605.	5.6	98
24	Immunoseroproteomic Profiling in African American Men with Prostate Cancer: Evidence for an Autoantibody Response to Glycolysis and Plasminogen-Associated Proteins. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3564-3580.	3.8	21
25	Autoantibody response to Sui1 and its tissue-specific expression in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 2547-2553.	1.8	8
26	Tumor-associated antigen CAPER1± and microvessel density in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 16985-16995.	1.8	13
27	Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer. <i>Oncotarget</i> , 2016, 7, 43546-43556.	1.8	14
28	Association of Polymorphisms in X-Ray Repair Cross Complementing 1 Gene and Risk of Esophageal Squamous Cell Carcinoma in a Chinese Population. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	10
29	Autoimmune response to PARP and BRCA1/BRCA2 in cancer. <i>Oncotarget</i> , 2015, 6, 11575-11584.	1.8	31
30	Competing endogenous RNA networks and gastric cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 11680.	3.3	161
31	Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma. <i>Oncology Reports</i> , 2015, 33, 2245-52.	2.6	10
32	Detection of autoantibodies to multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. <i>Tumor Biology</i> , 2015, 36, 1307-1312.	1.8	20
33	Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 829-852.	3.1	30
34	CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer. <i>Molecular BioSystems</i> , 2015, 11, 105-114.	2.9	14
35	p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancer. <i>Oncotarget</i> , 2015, 6, 32656-32668.	1.8	32
36	Restricted Boltzmann Machines for Classification of Hepatocellular Carcinoma. <i>Computational Biology Journal</i> , 2014, 2014, 1-5.	0.6	7

#	ARTICLE	IF	CITATIONS
37	Identification of glutathione S-transferase omega 1 (GSTO1) protein as a novel tumor-associated antigen and its autoantibody in human esophageal squamous cell carcinoma. <i>Tumor Biology</i> , 2014, 35, 10871-10877.	1.8	28
38	Humoral Autoimmune Responses to Insulin-Like Growth Factor II mRNA-Binding Proteins IMP1 and p62/IMP2 in Ovarian Cancer. <i>Journal of Immunology Research</i> , 2014, 2014, 1-7.	2.2	12
39	Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens. <i>Journal of Immunology Research</i> , 2014, 2014, 1-9.	2.2	28
40	Autoantibody Response to Murine Double Minute 2 Protein in Immunodiagnosis of Hepatocellular Carcinoma. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	2.2	8
41	Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis. <i>Tumor Biology</i> , 2014, 35, 2661-2667.	1.8	16
42	A cancer-related protein 14-3-3 $\eta$ is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma. <i>Tumor Biology</i> , 2014, 35, 4247-4256.	1.8	21
43	Overexpression of HCC1/CAPER1 may play a role in lung cancer carcinogenesis. <i>Tumor Biology</i> , 2014, 35, 6311-6317.	1.8	21
44	Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma. <i>Clinical Immunology</i> , 2014, 152, 127-139.	3.2	46
45	CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer. <i>Oncology Reports</i> , 2014, 32, 1683-1694.	2.6	25
46	Mini-Array of Multiple Tumor-associated Antigens (TAAs) in the Immunodiagnosis of Esophageal Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 2635-2640.	1.2	15
47	Biotherapy for Autoimmune Liver Diseases. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 510-515.	1.6	2
48	Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC). <i>Experimental Hematology and Oncology</i> , 2013, 2, 15.	5.0	29
49	Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis. <i>Autoimmunity Reviews</i> , 2013, 12, 1123-1128.	5.8	41
50	Using Immunoproteomics to Identify Alpha-enolase as an Autoantigen in Liver Fibrosis. <i>Journal of Proteome Research</i> , 2013, 12, 1789-1796.	3.7	42
51	Effect of Cerium Oxide Nanoparticles on Rice: A Study Involving the Antioxidant Defense System and In Vivo Fluorescence Imaging. <i>Environmental Science &amp; Technology</i> , 2013, 47, 5635-5642.	10.0	289
52	Stress Response and Tolerance of Zea mays to CeO <sub>2</sub> Nanoparticles: Cross Talk among H <sub>2</sub> O <sub>2</sub> , Heat Shock Protein, and Lipid Peroxidation. <i>ACS Nano</i> , 2012, 6, 9615-9622.	14.6	254
53	Using Proteomic Approach to Identify Tumor-Associated Proteins as Biomarkers in Human Esophageal Squamous Cell Carcinoma. <i>Journal of Proteome Research</i> , 2011, 10, 2863-2872.	3.7	122
54	Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. <i>Autoimmunity Reviews</i> , 2011, 10, 331-335.	5.8	61

#	ARTICLE	IF	CITATIONS
55	Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 321-328.	3.1	74
56	Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. <i>Cancer Letters</i> , 2010, 289, 32-39.	7.2	52
57	Identification of Tumor-Associated Antigens as Diagnostic and Predictive Biomarkers in Cancer. <i>Methods in Molecular Biology</i> , 2009, 520, 1-10.	0.9	21
58	Using Proteomic Approach to Identify Tumor-Associated Antigens as Markers in Hepatocellular Carcinoma. <i>Journal of Proteome Research</i> , 2008, 7, 4004-4012.	3.7	65
59	Detection of autoantibodies to multiple tumor-associated antigens in the immunodiagnosis of ovarian cancer. <i>Molecular Medicine Reports</i> , 2008, 1, 589-94.	2.4	16
60	Autoantibodies to Ca <sup>2+</sup> binding protein Calnuc is a potential marker in colon cancer detection. <i>International Journal of Oncology</i> , 2007, , .	3.3	13
61	Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2007, 46, 107-114.	3.7	93
62	Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma. <i>Autoimmunity Reviews</i> , 2007, 6, 143-148.	5.8	25
63	Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. <i>European Journal of Haematology</i> , 2007, 79, 210-225.	2.2	31
64	Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. <i>Oncology Reports</i> , 2006, 16, 1105.	2.6	24
65	Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. <i>Oncology Reports</i> , 2006, 16, 1105-10.	2.6	60
66	Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. <i>Cancer Detection and Prevention</i> , 2005, 29, 241-248.	2.1	45
67	Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. <i>Prostate</i> , 2005, 63, 252-258.	2.3	55
68	Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2005, 26, 311.	3.3	12
69	Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2005, 27, 1079.	3.3	18
70	Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2005, 26, 311-7.	3.3	19
71	Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2005, 27, 1079-85.	3.3	20
72	Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. <i>Cancer Detection and Prevention</i> , 2004, 28, 114-118.	2.1	42

#	ARTICLE	IF	CITATIONS
73	Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 136-43.	2.5	122
74	Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. <i>Clinical Cancer Research</i> , 2003, 9, 5120-6.	7.0	128
75	Autoantibody responses in Chinese hepatocellular carcinoma. <i>Journal of Clinical Immunology</i> , 2002, 22, 98-105.	3.8	18
76	Autoimmune Responses to mRNA Binding Proteins p62 and Koc in Diverse Malignancies. <i>Clinical Immunology</i> , 2001, 100, 149-156.	3.2	60
77	Aberrant Expression of Fetal RNA-Binding Protein p62 in Liver Cancer and Liver Cirrhosis. <i>American Journal of Pathology</i> , 2001, 159, 945-953.	3.8	92
78	A Novel Cytoplasmic Protein with RNA-binding Motifs Is an Autoantigen in Human Hepatocellular Carcinoma. <i>Journal of Experimental Medicine</i> , 1999, 189, 1101-1110.	8.5	191